Standing out in the field of IgY Immunotechnology

  • Home
    Home A full collection of all the Research Archive entries.
  • Years
    Years Sort entries by year.
  • Tags
    Tags Displays a list of tags that have been used in the blog.
  • Archives
    Archives Contains a list of research entries that were created previously.

Preparation of egg yolk antibodies against BoNT/B and their passive protection in mouse models.

Posted by on in 2014
  • Font size: Larger Smaller
  • Hits: 2772
  • Print

You ZYang HXin WKang LGao SWang JZhang TWang JL. 2014. Hum Vaccin Immunother. 210(8) 

2321-7. [Epub ahead of print]


Botulism in human is a devastating intoxication caused mainly by type A, B, and E botulinum neurotoxins (BoNTs). The most effective treatment of botulism is injection of BoNT antiserum in the first 24 h. In this study, a recombinant C-terminal heavy chain of BoNT/B (BHc) was successfully expressed in E. coli. The soluble BHc was used as an antigen to immunize laying hens for yolk immunoglobulin (IgY) production. The purified IgYagainst BHc subunit, preincubated with the BoNT/B, was predominantly involved in the neutralization of BoNT/B toxicity. Furthermore, both intraperitoneal and intragastric administration of the IgY could protect mice from death caused by injection of toxin at a lethal dose. Our results therefore suggest that anti-BHc IgY directed to the Hc domain is effectively involved in the neutralization of BoNT/B toxin and may be considered as preventive and therapeutic intervention in the case of botulism.


Hc fragment; IgY; botulinum neurotoxin; botulism; passive protection

[PubMed - as supplied by publisher]
Last modified on